COVID-19 and Outpatient Parenteral Antimicrobial Therapy: The Need to Protect Vulnerable Medicare Beneficiaries.
Where this comes from
- Record sourced from PubMed, PMID 32422072.
- Also identified by DOI 10.7326/M20-1774 and PMC identifier 7233184.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Home infusion therapy can provide a safer alternative for exposure to SARS-CoV-2 infection for many vulnerable patients who receive parenteral therapies on an outpatient basis, such as parenteral antimicrobial therapy. This article proposes changes to Medicare payment policy, which currently does not adequately reimburse for these services for many patients.
Medical subject headings
- Anti-Infective Agents
- Coronavirus Infections
- Home Infusion Therapy
- Medicare
- Pneumonia, Viral